{"Title": ["Health Care Sector Update for 12/03/2019: MACK,AGTC,VRAY,MDT,ARWR", "Health Care Sector Update for 04/05/2019: SYRS, AQB, MACK, JNJ, PFE, ABT, MRK, AMGN", "MACK Halts MM-310 Study, VKTX On Watch, NAII Hits New High", "Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4", "Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely?", "Merrimack (MACK) Down 7.5% Since Last Earnings Report: Can It Rebound?", "Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3", "5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings", "Health Care Sector Update for 12/03/2019: MACK,AGTC,VRAY,MDT,ARWR", "Health Care Sector Update for 10/19/2018: EYPT, MACK, DCPH", "Health Care Sector Update for 10/19/2018: MACK, AVXL, CLVS, JNJ, PFE, ABT, MRK, AMGN", "Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts", "Merrimack (MACK) Up 6.7% Since Last Earnings Report: Can It Continue?", "Health Care Sector Update for 09/06/2018: MACK,KALV,NVCR,TLRY", "Zacks.com highlights: American Woodmark, Adverum Biotechnologies, Merrimack Pharmaceuticals, Athene Holding and M&T Bank", "Move Beyond Bargain Hunting: 5 Stocks With Rising P/E", "Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod", "Merrimack (MACK) Reports Wider-than-Expected Q2 Loss", "Earnings Reaction History: Merrimack Pharmaceuticals Inc, 44.4% Follow-Through Indicator, 4.8% Sensitive", "Is a Beat in the Cards for Merrimack (MACK) in Q2 Earnings?", "Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod", "Merrimack Crashes as Phase II Pancreatic Cancer Study Fails", "Mid-Morning Market Update: Markets Open Lower; Carnival Cuts Profit Forecast", "Mid-Afternoon Market Update: NASDAQ Down Over 2.5%; Xerium Technologies Shares Spike Higher", "Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2", "Options Traders Expect Huge Moves in Merrimack Pharmaceuticals (MACK) Stock", "Noteworthy Thursday Option Activity: IRBT, MACK, CRR", "Why is Merrimack (MACK) Up 6.3% Since Its Last Earnings Report?", "Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1", "Merrimack (MACK) Reports Wider-than-Expected Q1 Loss", "What's in the Cards for Merrimack (MACK) in Q1 Earnings?", "Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4", "Noteworthy Friday Option Activity: MACK, IBM, CCL", "Options Traders Expect Huge Moves in Merrimack Pharmaceuticals (MACK) Stock", "Noteworthy Thursday Option Activity: IRBT, MACK, CRR", "Why is Merrimack (MACK) Up 6.3% Since Its Last Earnings Report?", "Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1", "Merrimack (MACK) Reports Wider-than-Expected Q1 Loss", "What's in the Cards for Merrimack (MACK) in Q1 Earnings?", "Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4", "Noteworthy Friday Option Activity: MACK, IBM, CCL", "Options Traders Expect Huge Moves in Merrimack Pharmaceuticals (MACK) Stock", "Noteworthy Thursday Option Activity: IRBT, MACK, CRR", "Why is Merrimack (MACK) Up 6.3% Since Its Last Earnings Report?", "Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1", "Merrimack (MACK) Reports Wider-than-Expected Q1 Loss", "What's in the Cards for Merrimack (MACK) in Q1 Earnings?", "Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4", "Noteworthy Friday Option Activity: MACK, IBM, CCL", "Merrimack (MACK) Down 7.8% Since Earnings Report: Can It Rebound?", "Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up", "Merrimack's (MACK) Reports Narrower-than-Expected Q3 Loss", "Earnings Reaction History: Merrimack Pharmaceuticals Inc, 33.3% Follow-Through Indicator, 4.3% Sensitive", "What's in the Cards for Merrimack (MACK) in Q3 Earnings?", "Health Care Sector Update for 10/13/2017: MACK", "Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls", "What's in the Cards for Merrimack (MACK) in Q4 Earnings?", "Health Care Sector Update for 05/26/2017: VEEV,SENS,MACK", "Merrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde", "Merrimack's (MACK) Reports Wider-than-Expected Q1 Loss", "Earnings Reaction History: Merrimack Pharmaceuticals Inc, 36.4% Follow-Through Indicator, 4.2% Sensitive", "What's in the Cards for Merrimack (MACK) in Q1 Earnings?", "Are Options Traders Betting on a Big Move in Merrimack (MACK) Stock?", "Merrimack (MACK) Starts Enrollment in Solid Tumors Study", "Health Care Sector Update for 05/26/2017: KITE,SENS,MACK", "Health Care Sector Update for 03/01/2017: MACK", "Merrimack's (MACK) Q4 Loss In-Line With Estimates", "Earnings Reaction History: Merrimack Pharmaceuticals Inc, 36.4% Follow-Through Indicator, 7.9% Sensitive", "Merrimack Pharmaceuticals Inc (MACK) Stock Soars on Ipsen Deal", "Here's Why Merrimack Pharmaceuticals Inc. Fell 47.3% in 2016", "Why Merrimack Pharmaceuticals Stock Is Roaring Higher Today", "Pre-Market Most Active for Jan 9, 2017 : ARIA, MACK, SMI, BAC, TLT, MPEL, FIT, RIO, ARWR, NVS, VALE, TVIX", "Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?", "Is the Options Market Predicting a Spike in Merrimack (MACK) Stock?", "Company News for January 10, 2017", "Pre-Market Most Active for Jan 10, 2017 : WMB, VRX, ING, UGP, FCX, TTM, VOD, TLT, TVIX, MACK, QQQ, ILMN", "Merrimack Pharmaceuticals Inc (MACK) Stock Soars on Ipsen Deal", "Here's Why Merrimack Pharmaceuticals Inc. Fell 47.3% in 2016", "Why Merrimack Pharmaceuticals Stock Is Roaring Higher Today", "Merrimack (MACK) Q3 Loss Lower than Expected, Stock Up", "Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B", "Here's Why These Biopharma Stocks Soared at Least 10% Today", "Health Care Sector Update for 11/09/2016: MACK,SCMP,CYH", "Earnings Reaction History: Merrimack Pharmaceuticals Inc, 40.0% Follow-Through Indicator, 7.1% Sensitive", "Merrimack (MACK): What Awaits the Stock in Q3 Earnings?", "Merrimack Pharmaceuticals (MACK) Worth a Look: Stock Up 8.2%", "Shire Cancer Drug Onivyde Receives EU Marketing Approval", "Will Positive Phase 3 Results Get Merrimack Back on Track?", "Why Merrimack Pharmaceuticals, Inc. Shares Sank 18% Lower in October", "Merrimack's Onivyde Positive in Pancreatic Cancer Study", "Why Merrimack Pharmaceuticals Inc. Rose 38% in September", "Company News for October 04, 2016", "Health Care Sector Update for 10/03/2016: MYL,WFC,RMR,FVE,MACK", "Health Care Sector Update for 10/03/2016: CXRX,FVE,MACK", "Why Merrimack Pharmaceuticals Inc Fell 20.3% in August", "What Makes Merrimack Pharmaceuticals (MACK) a Strong Sell?", "How Risky Is Merrimack Pharmaceuticals Stock?", "Merrimack's Onivyde Positive in Pancreatic Cancer Study", "Why Merrimack Pharmaceuticals Inc. Rose 38% in September", "ZIOPHARM (ZIOP) Stock Down on Patient Death in Phase I", "Celgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma", "Gilead's HCV Drug Epclusa Gets Regulatory Nod in Canada", "Ultragenyx (RARE) Reports Positive Phase III rhGUS Data", "Merrimack Pharmaceuticals Stock Sank Like a Stone in June", "Merrimack (MACK) Q2 Loss Wider than Expected, Sales Top", "Comeback for Juno (JUNO) Stock? FDA Lifts Clinical Hold", "Bayer Expands Drug Discovery Collaboration with X-Chem", "Merrimack Stock Up on Fast Track Status for Seribantumab", "Buy 5 Attractive Biotechs at Bargain Prices", "Add Up The Parts: XBI Could Be Worth $80", "Here's Why Merrimack Pharmaceuticals' Stock Has Been Getting Crushed in 2016", "BioDelivery Sciences (BDSI) Catches Eye: Stock Rises 12%", "CytRx (CYTR) Stock Falls on Unfavorable Aldoxorubicin Data", "Comeback for Juno (JUNO) Stock? FDA Lifts Clinical Hold", "Why Merrimack Pharmaceuticals' Stock Is Sliding Today", "Merrimack (MACK) Posts Narrower-than-Expected Loss in Q1", "Earnings Reaction History: Merrimack Pharmaceuticals Inc, 44.4% Follow-Through Indicator, 8.8% Sensitive", "Merrimack (MACK) Q1 Earnings: What's Ahead for the Stock?", "Zacks Investment Ideas feature highlights: Juno Therapeutics, Genocea Biosciences, Merrimack Pharmaceuticals and BioShares Biotechnology Clinical Trials ETF", "The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics", "MACK Makes Bullish Cross Above Critical Moving Average", "Merrimack Pharmaceuticals Inc Rose 28% in March. Here's Why.", "Merrimack Director buys 15,000 shares", "Merrimack Pharmaceuticals (MACK) Jumps: Stock Rises 12.6%", "Why Merrimack Pharmaceuticals Inc. Shares Are Off to the Races", "Merrimack Q4 Loss in Line with Estimates, Revenues Miss", "What's in Store for Merrimack (MACK) this Earnings Season?", "3 Biotech Stocks With Scary-High Debt-to-Capital Ratios", "MACK Makes Bullish Cross Above Critical Moving Average", "Merrimack Pharmaceuticals Inc Rose 28% in March. Here's Why.", "Merrimack Alters Endpoint in Cancer Drug Trial, Raises Funds", "Momenta's Cancer Study Enrolment Put on Temporary Hold", "Why Merrimack Pharmaceuticals Inc Is Selling Off Today", "Merrimack (MACK) Reports Narrower-than-Expected Q3 Loss", "Earnings Reaction History: Merrimack Pharmaceuticals Inc, 33.3% Follow-Through Indicator, 7.1% Sensitive", "The Math Shows IHE Can Go To $203", "After Hours Most Active for Feb 9, 2016 : BAC, ETE, RF, ETP, EPD, RDN, MU, QQQ, SCTY, MACK, MSFT, ON", "Merrimack Reports Positive Onivyde Data in Pancreatic Cancer", "Merrimack Alters Endpoint in Cancer Drug Trial, Raises Funds", "Momenta's Cancer Study Enrolment Put on Temporary Hold", "Why Merrimack Pharmaceuticals Inc Is Selling Off Today", "Merrimack (MACK) Reports Narrower-than-Expected Q3 Loss", "Earnings Reaction History: Merrimack Pharmaceuticals Inc, 33.3% Follow-Through Indicator, 7.1% Sensitive", "The Math Shows IHE Can Go To $203", "Will Merrimack (MACK) Surprise Estimates in Q3 Earnings?", "Will Intercept (ICPT) Beat Estimates in Q3 Earnings?", "Catalyst Pharmaceutical (CPRX): A Peek into Q3 Earnings", "Will Inovio (INO) Disappoint Investors this Earnings Season?", "What Awaits Ligand Pharmaceuticals (LGND) in Q3 Earnings?", "Will Isis Pharmaceuticals (ISIS) Surprise in Q3 Earnings?", "Is Intrexon (XON) Likely to Disappoint This Earnings Season?", "Will Puma Biotechnology (PBYI) Surprise in Q3 Earnings?", "Will Merrimack (MACK) Surprise Estimates in Q3 Earnings?", "Will Intercept (ICPT) Beat Estimates in Q3 Earnings?", "Catalyst Pharmaceutical (CPRX): A Peek into Q3 Earnings", "Will Inovio (INO) Disappoint Investors this Earnings Season?", "What Awaits Ligand Pharmaceuticals (LGND) in Q3 Earnings?", "Will Isis Pharmaceuticals (ISIS) Surprise in Q3 Earnings?", "Is Intrexon (XON) Likely to Disappoint This Earnings Season?", "What's in Store for Repros (RPRX) this Earnings Season?", "Celgene (CELG) to Report Q3 Earnings: What to Expect?", "Horizon (HZNP): What's in Store this Earnings Season?", "Will Agios (AGIO) Disappoint Investors this Earnings Season?", "Quanta Services (PWR) Q3 Earnings: Will It Disappoint?", "Synta (SNTA) Q3 Earnings Preview: What's in the Cards?", "Can Endo International's (ENDP) Q3 Earnings Surprise?", "Will BioDelivery (BDSI) Disappoint Estimates in Q3 Earnings?", "Will Aerie (AERI) Post a Wider-Than-Expected Loss in Q3?", "Will AVEO (AVEO) Pull a Surprise this Earnings Season?", "What's in Store for Conatus (CNAT) this Earnings Season?", "What to Expect from Radius (RDUS) This Earnings Season", "Can Celldex (CLDX) Surprise Estimates in Q3 Earnings?", "What's in Store for Endocyte (ECYT) This Earnings Season?", "Will Epizyme (EPZM) Disappoint This Earnings Season?", "Will Arena's (ARNA) Q3 Loss be Narrower-than-Expected?", "Can Mylan (MYL) Surprise Investors This Earnings Season?", "Earnings Reaction History: Merrimack Pharmaceuticals Inc, 25.0% Follow-Through Indicator, 7.2% Sensitive", "Merrimack Pharmaceuticals (MACK): Q2 Earnings Preview - Analyst Blog", "Merrimack Pharmaceuticals' Stock Tanked in July: Is It Now a Buy?", "Merrimack Pharmaceuticals Enters Oversold Territory (MACK)", "Baxter's MAA for MM-398 Accepted in International Markets - Analyst Blog", "Merrimack Pharmaceuticals (MACK) Catches Eye: Stock Up 5.8%", "Merrimack Pharmaceuticals' Q2 Loss Wider, Revenues Up - Analyst Blog", "Why Merrimack Pharmaceuticals Inc is Soaring Today", "Earnings Reaction History: Merrimack Pharmaceuticals Inc, 25.0% Follow-Through Indicator, 7.2% Sensitive", "Earnings Reaction History: Merrimack Pharmaceuticals Inc, 28.6% Follow-Through Indicator, 7.6% Sensitive", "Merrimack Pharmaceuticals (MACK): A Miss this Earnings? - Analyst Blog", "First Week of December 18th Options Trading For Merrimack Pharmaceuticals (MACK)", "Merrimack Pharmaceuticals Q4 Loss Narrower Than Expected - Analyst Blog", "Health Care Sector Update for 06/25/2015: OPRN, ESPR, MACK", "Merrimack Pharmaceuticals' MM-398 in Breast Cancer Study - Analyst Blog", "Merrimack Reveals Additional Data from Oncology Candidate - Analyst Blog", "After Hours Most Active for Jan 20, 2015 : BAC, PFE, EMC, AAPL, QQQ, NFLX, FCX, INTC, JPM, IBM, GILD, MACK", "Friday 12/26 Insider Buying Report: MACK", "Insiders Bullish on Certain Holdings of XBI", "Health Care Sector Update for 11/21/2014: OREX, MACK", "Merrimack Pharmaceuticals' (MACK) Loss Narrows in Q4 - Tale of the Tape", "Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog", "Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog", "Is a Surprise Coming for Merrimack Pharmaceuticals (MACK) This Earnings Season? - Tale of the Tape", "What's in Store for TrovaGene (TROV) This Earnings Season? - Analyst Blog", "Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog", "Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% - Tale of the Tape", "Alder Biopharmaceuticals (ALDR) Jumps: Stock Rises 6.5% - Tale of the Tape", "Merrimack Pharmaceuticals' MM-398 Gets Fast Track Status - Analyst Blog", "Cara Therapeutics (CARA) Worth Watching: Stock Rises 6.4% - Tale of the Tape", "Verastem (VSTM) Shows Strength: Stock Adds 7% in Session - Tale of the Tape", "Merrimack Pharmaceuticals (MACK) Shares March Higher, Can It Continue? - Tale of the Tape", "Merrimack Pharmaceuticals (MACK) Looks Strong: Stock Up 8.6% - Tale of the Tape", "3 Biotech Stocks Near 52-Week Highs Worth Selling", "Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% - Tale of the Tape", "Novavax (NVAX) Moves Up: Stock Adds 10.1% in Session - Tale of the Tape", "Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% - Tale of the Tape", "Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 10.7% - Tale of the Tape", "Weakness Seen in Momenta Pharmaceuticals (MNTA): Stock Tumbles 13.5% - Tale of the Tape", "Why Merrimack (MACK) Could Be Positioned for a Surge? - Tale of the Tape", "Get Ready To Be Surprised This Earnings Season - Screen of the Week", "How Merrimack Pharmaceuticals (MACK) Stock Stands Out in a Strong Industry - Tale of the Tape", "Will Merrimack (MACK) Continue to Surge Higher? - Tale of the Tape", "Merrimack Pharmaceuticals (MACK) Soars: Stock Adds 7.4% is Session - Tale of the Tape", "Lexicon Pharmaceuticals (LXRX) Jumps: Stock Rises 15.7% - Tale of the Tape", "Why Merrimack Pharmaceuticals Inc Stock Is Soaring Today", "US Stocks Seen Opening Higher After 3-Day Decline Before Home Sales Data; ECB Provides Boost to Markets", "Sector Update: Health Care", "Sector Update: Health-Care Shares Flat Pre-Market", "Pre-Market Most Active for Sep 24, 2014 : AAPL, GSK, MACK, AVNR, SAN, BABA, ACOR, SIRI, TVIX, NOK, BAC, AZN", "US Futures Gain Ahead of New Home Sales; ECB's Draghi Voices Support For Markets", "Insider Bets Paying Off At MACK As New 52-Week High Reached", "Baxter and Merrimack Collaborate on Drug Development - Analyst Blog", "Can Merrimack Pharmaceuticals (MACK) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape", "Will Merrimack Pharmaceuticals (MACK) Crush Estimates at Its Next Earnings Report? - Tale of the Tape", "Insiders Buy the Holdings of XBI ETF", "Tuesday 6/24 Insider Buying Report: MACK, HERO", "Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights - Analyst Blog", "XBI, MNKD, MACK, RGEN: ETF Outflow Alert", "Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News - Analyst Blog", "After Hours Most Active for Sep 15, 2014 : QQQ, VMW, BAC, MACK, OXY, YOKU, SIRI, AA, CAT, MSFT, CSCO, ERIC", "Pre-Market Most Active for May 1, 2014 : NMR, S, MACK, FET, YELP, FB, BURL, TMUS", "Small Gains for Healthcare Sector; Merrimack Pharmaceuticals Soars After Cancer Drug Trial Success", "Insiders Seeing Green With MACK At New 52-Week High", "Notable Two Hundred Day Moving Average Cross - MACK", "Should You Worry About the Short Interest in Merrimack (MACK)? - Tale of the Tape", "After Hours Most Active for Jan 21, 2014 : PG, AMD, BAC, BSBR, ACG, IBM, MACK, QQQ, SPLS, CREE, ARCP, NUAN", "Can Merrimack Pharmaceuticals Inc. (MACK) Continue to Rise? - Tale of the Tape", "Sector Update: Healthcare", "Merrimack Pharmaceuticals (MACK) Jumps: Stock Rises 6.6% - Tale of the Tape", "Sector Update: Biotech Stocks Looking Strong As NASDAQ Struggles", "Update on Merrimack's MM-121 - Analyst Blog", "Little Movement for Healthcare Sector; Mack Pharmaceuticals Rising After Positive Indications in 2 Drug Trials", "Sector Update: Healthcare", "After Hours Most Active for Nov 11, 2013 : QQQ, BX, KMT, KKR, VLO, GM, FIG, VPHM, FB, MACK, HOLX, WEN", "Pre-Market Most Active for Oct 30, 2013 : TEVA, S, WU, GM, NOK, HCA, FB, ARIA, BIDU, EXEL, MACK, SODA", "In Insider Trading, a Buy at Merrimack Pharmaceuticals", "Merrimack Pharmaceuticals (MACK) Jumps: Stock Rises 6.6% - Tale of the Tape", "Sector Update: Biotech Stocks Looking Strong As NASDAQ Struggles", "Update on Merrimack's MM-121 - Analyst Blog", "Pre-Market Most Active for Jul 12, 2013 : JPM, BAC, VOD, FLY, WFC, MACK, SIRI, NOK, HMC, ZNGA, SPRD, QQQ", "Sanofi/MACK Candidate Progresses - Analyst Blog", "After Hours Most Active for Nov 16, 2012 : SFD, QQQ, WIN, TSN, MSFT, TSS, BAC, MYL, ZGNX, WM, MACK, MMC", "Street research for Merrimack Pharmaceuticals expected on May 8", "Merrimack Study Data Published - Analyst Blog", "Merrimack Pharmaceuticals sets new terms, now seeking $100 million", "10 US IPOs planned for the week of Mar 26", "Merrimack prices IPO at $7, raising $100 million in proceeds"], "Elapsed Time": ["DEC 3, 2019", "APR 5, 2019", "APR 4, 2019", "MAR 7, 2019", "FEB 11, 2019", "DEC 7, 2018", "NOV 9, 2018", "NOV 5, 2018", "DEC 3, 2019", "OCT 19, 2018", "OCT 19, 2018", "OCT 11, 2018", "SEP 6, 2018", "SEP 6, 2018", "SEP 4, 2018", "AUG 31, 2018", "OCT 24, 2018", "AUG 7, 2018", "AUG 7, 2018", "AUG 1, 2018", "JUN 27, 2018", "JUN 26, 2018", "JUN 25, 2018", "JUN 25, 2018", "AUG 8, 2018", "JUN 15, 2018", "JUN 14, 2018", "JUN 7, 2018", "MAY 9, 2018", "MAY 8, 2018", "MAY 3, 2018", "MAR 13, 2018", "JUN 22, 2018", "JUN 15, 2018", "JUN 14, 2018", "JUN 7, 2018", "MAY 9, 2018", "MAY 8, 2018", "MAY 3, 2018", "MAR 13, 2018", "JUN 22, 2018", "JUN 15, 2018", "JUN 14, 2018", "JUN 7, 2018", "MAY 9, 2018", "MAY 8, 2018", "MAY 3, 2018", "MAR 13, 2018", "JUN 22, 2018", "DEC 11, 2017", "NOV 9, 2017", "NOV 8, 2017", "NOV 8, 2017", "NOV 6, 2017", "OCT 13, 2017", "AUG 10, 2017", "FEB 23, 2018", "MAY 26, 2017", "MAY 11, 2017", "MAY 10, 2017", "MAY 10, 2017", "APR 27, 2017", "MAR 31, 2017", "MAR 24, 2017", "MAY 26, 2017", "MAR 1, 2017", "MAR 1, 2017", "MAR 1, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 17, 2017", "JAN 11, 2017", "JAN 10, 2017", "JAN 10, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "NOV 11, 2016", "JAN 9, 2017", "NOV 9, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 8, 2016", "OCT 24, 2016", "OCT 19, 2016", "OCT 14, 2016", "NOV 9, 2016", "OCT 12, 2016", "OCT 10, 2016", "OCT 4, 2016", "OCT 3, 2016", "OCT 3, 2016", "SEP 12, 2016", "AUG 29, 2016", "OCT 13, 2016", "OCT 12, 2016", "AUG 1, 2016", "JUL 18, 2016", "JUL 18, 2016", "JUL 15, 2016", "JUL 15, 2016", "JUL 13, 2016", "AUG 5, 2016", "JUL 13, 2016", "JUL 13, 2016", "JUL 7, 2016", "JUL 5, 2016", "JUN 28, 2016", "JUN 27, 2016", "JUL 13, 2016", "JUL 13, 2016", "MAY 20, 2016", "MAY 3, 2016", "MAY 3, 2016", "MAY 2, 2016", "APR 27, 2016", "APR 11, 2016", "JUN 9, 2016", "APR 7, 2016", "APR 7, 2016", "MAR 4, 2016", "MAR 2, 2016", "MAR 1, 2016", "FEB 26, 2016", "FEB 22, 2016", "APR 11, 2016", "APR 7, 2016", "APR 7, 2016", "DEC 23, 2015", "NOV 16, 2015", "NOV 10, 2015", "NOV 10, 2015", "NOV 9, 2015", "FEB 16, 2016", "FEB 9, 2016", "JAN 20, 2016", "DEC 23, 2015", "NOV 16, 2015", "NOV 10, 2015", "NOV 10, 2015", "NOV 9, 2015", "FEB 16, 2016", "NOV 6, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 5, 2015", "NOV 5, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 5, 2015", "NOV 5, 2015", "NOV 6, 2015", "NOV 5, 2015", "NOV 4, 2015", "NOV 4, 2015", "NOV 4, 2015", "NOV 3, 2015", "NOV 3, 2015", "NOV 3, 2015", "NOV 5, 2015", "NOV 2, 2015", "NOV 2, 2015", "NOV 2, 2015", "NOV 2, 2015", "NOV 2, 2015", "NOV 2, 2015", "NOV 2, 2015", "OCT 30, 2015", "OCT 28, 2015", "AUG 10, 2015", "AUG 7, 2015", "AUG 7, 2015", "JUL 21, 2015", "JUN 29, 2015", "AUG 12, 2015", "AUG 11, 2015", "AUG 11, 2015", "MAY 8, 2015", "MAY 7, 2015", "MAY 5, 2015", "APR 27, 2015", "FEB 27, 2015", "JUN 25, 2015", "JUN 15, 2015", "JAN 22, 2015", "JAN 20, 2015", "DEC 26, 2014", "DEC 24, 2014", "NOV 21, 2014", "FEB 26, 2015", "NOV 7, 2014", "NOV 7, 2014", "NOV 5, 2014", "NOV 5, 2014", "NOV 4, 2014", "NOV 3, 2014", "NOV 3, 2014", "NOV 20, 2014", "OCT 30, 2014", "OCT 27, 2014", "OCT 27, 2014", "OCT 24, 2014", "OCT 22, 2014", "OCT 20, 2014", "OCT 17, 2014", "OCT 31, 2014", "OCT 16, 2014", "OCT 13, 2014", "OCT 10, 2014", "OCT 7, 2014", "SEP 29, 2014", "SEP 26, 2014", "SEP 26, 2014", "OCT 17, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 25, 2014", "SEP 9, 2014", "AUG 20, 2014", "JUL 8, 2014", "JUN 24, 2014", "JUN 23, 2014", "JUN 11, 2014", "MAY 7, 2014", "SEP 15, 2014", "MAY 1, 2014", "MAY 1, 2014", "MAY 1, 2014", "APR 14, 2014", "MAR 5, 2014", "JAN 21, 2014", "JAN 9, 2014", "MAY 1, 2014", "DEC 3, 2013", "DEC 2, 2013", "NOV 29, 2013", "NOV 26, 2013", "NOV 26, 2013", "NOV 11, 2013", "OCT 30, 2013", "DEC 3, 2013", "DEC 3, 2013", "DEC 2, 2013", "JUL 26, 2013", "JUL 12, 2013", "MAR 20, 2013", "NOV 16, 2012", "MAY 3, 2012", "AUG 23, 2013", "MAR 26, 2012", "MAR 26, 2012", "MAR 28, 2012"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/health-care-sector-update-for-12-03-2019%3A-mackagtcvraymdtarwr-2019-12-03", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-05-2019%3A-syrs-aqb-mack-jnj-pfe-abt-mrk-amgn-2019-04-05", "https://www.nasdaq.com/articles/mack-halts-mm-310-study-vktx-watch-naii-hits-new-high-2019-04-05", "https://www.nasdaq.com/articles/merrimack-mack-incurs-narrower-than-expected-loss-in-q4-2019-03-07", "https://www.nasdaq.com/articles/merrimack-mack-stock-up-year-to-date%3A-is-a-rebound-likely-2019-02-11", "https://www.nasdaq.com/articles/merrimack-mack-down-7.5-since-last-earnings-report%3A-can-it-rebound-2018-12-07", "https://www.nasdaq.com/articles/merrimack-mack-suffers-wider-than-expected-loss-in-q3-2018-11-09", "https://www.nasdaq.com/articles/5-drug-biotech-stocks-set-to-trump-estimates-in-q3-earnings-2018-11-05", "https://www.nasdaq.com/articles/health-care-sector-update-for-12-03-2019%3A-mackagtcvraymdtarwr-2019-12-03", "https://www.nasdaq.com/articles/health-care-sector-update-10192018-eypt-mack-dcph-2018-10-19", "https://www.nasdaq.com/articles/health-care-sector-update-10192018-mack-avxl-clvs-jnj-pfe-abt-mrk-amgn-2018-10-19", "https://www.nasdaq.com/articles/merrimack-mack-focuses-on-early-stage-pipeline-and-cost-cuts-2018-10-11", "https://www.nasdaq.com/articles/merrimack-mack-up-6.7-since-last-earnings-report%3A-can-it-continue-2018-09-06", "https://www.nasdaq.com/articles/health-care-sector-update-09062018-mackkalvnvcrtlry-2018-09-06", "https://www.nasdaq.com/articles/zacks.com-highlights%3A-american-woodmark-adverum-biotechnologies-merrimack-pharmaceuticals", "https://www.nasdaq.com/articles/move-beyond-bargain-hunting-5-stocks-rising-pe-2018-08-31", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-biib-tops-mack-plunges-regns-asthma-drug-gets-fda-nod-2018-10-24", "https://www.nasdaq.com/articles/merrimack-mack-reports-wider-than-expected-q2-loss-2018-08-07", "https://www.nasdaq.com/articles/earnings-reaction-history-merrimack-pharmaceuticals-inc-444-follow-through-indicator-48", "https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-merrimack-mack-in-q2-earnings-2018-08-01", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-pbyi-soars-mack-crashes-gilds-biktarvy-gets-ec-nod-2018-06-27", "https://www.nasdaq.com/articles/merrimack-crashes-as-phase-ii-pancreatic-cancer-study-fails-2018-06-26", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-carnival-cuts-profit-forecast-2018-06-25", "https://www.nasdaq.com/articles/mid-afternoon-market-update-nasdaq-down-over-25-xerium-technologies-shares-spike-higher", "https://www.nasdaq.com/articles/merrimack-mack-suffers-wider-than-expected-loss-in-q2-2018-08-08", "https://www.nasdaq.com/articles/options-traders-expect-huge-moves-in-merrimack-pharmaceuticals-mack-stock-2018-06-15", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-irbt-mack-crr-2018-06-14", "https://www.nasdaq.com/articles/why-is-merrimack-mack-up-6.3-since-its-last-earnings-report-2018-06-07", "https://www.nasdaq.com/articles/merrimack-mack-reports-wider-than-expected-loss-in-q1-2018-05-09", "https://www.nasdaq.com/articles/merrimack-mack-reports-wider-than-expected-q1-loss-2018-05-08", "https://www.nasdaq.com/articles/whats-in-the-cards-for-merrimack-mack-in-q1-earnings-2018-05-03", "https://www.nasdaq.com/articles/merrimack-mack-incurs-narrower-than-expected-loss-in-q4-2018-03-13", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-mack-ibm-ccl-2018-06-22", "https://www.nasdaq.com/articles/options-traders-expect-huge-moves-in-merrimack-pharmaceuticals-mack-stock-2018-06-15", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-irbt-mack-crr-2018-06-14", "https://www.nasdaq.com/articles/why-is-merrimack-mack-up-6.3-since-its-last-earnings-report-2018-06-07", "https://www.nasdaq.com/articles/merrimack-mack-reports-wider-than-expected-loss-in-q1-2018-05-09", "https://www.nasdaq.com/articles/merrimack-mack-reports-wider-than-expected-q1-loss-2018-05-08", "https://www.nasdaq.com/articles/whats-in-the-cards-for-merrimack-mack-in-q1-earnings-2018-05-03", "https://www.nasdaq.com/articles/merrimack-mack-incurs-narrower-than-expected-loss-in-q4-2018-03-13", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-mack-ibm-ccl-2018-06-22", "https://www.nasdaq.com/articles/options-traders-expect-huge-moves-in-merrimack-pharmaceuticals-mack-stock-2018-06-15", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-irbt-mack-crr-2018-06-14", "https://www.nasdaq.com/articles/why-is-merrimack-mack-up-6.3-since-its-last-earnings-report-2018-06-07", "https://www.nasdaq.com/articles/merrimack-mack-reports-wider-than-expected-loss-in-q1-2018-05-09", "https://www.nasdaq.com/articles/merrimack-mack-reports-wider-than-expected-q1-loss-2018-05-08", "https://www.nasdaq.com/articles/whats-in-the-cards-for-merrimack-mack-in-q1-earnings-2018-05-03", "https://www.nasdaq.com/articles/merrimack-mack-incurs-narrower-than-expected-loss-in-q4-2018-03-13", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-mack-ibm-ccl-2018-06-22", "https://www.nasdaq.com/articles/merrimack-mack-down-7.8-since-earnings-report%3A-can-it-rebound-2017-12-11", "https://www.nasdaq.com/articles/merrimack-mack-q3-loss-narrower-than-expected-stock-up-2017-11-09", "https://www.nasdaq.com/articles/merrimacks-mack-reports-narrower-than-expected-q3-loss-2017-11-08", "https://www.nasdaq.com/articles/earnings-reaction-history-merrimack-pharmaceuticals-inc-333-follow-through-indicator-43", "https://www.nasdaq.com/articles/whats-in-the-cards-for-merrimack-mack-in-q3-earnings-2017-11-06", "https://www.nasdaq.com/articles/health-care-sector-update-10132017-mack-2017-10-13", "https://www.nasdaq.com/articles/merrimack-mack-q2-loss-wider-than-expected-stock-falls-2017-08-10", "https://www.nasdaq.com/articles/whats-in-the-cards-for-merrimack-mack-in-q4-earnings-2018-02-23", "https://www.nasdaq.com/articles/health-care-sector-update-05262017-veevsensmack-2017-05-26", "https://www.nasdaq.com/articles/merrimack-mack-q1-loss-wider-than-expected-sells-onivyde-2017-05-11", "https://www.nasdaq.com/articles/merrimacks-mack-reports-wider-expected-q1-loss-2017-05-10", "https://www.nasdaq.com/articles/earnings-reaction-history-merrimack-pharmaceuticals-inc-364-follow-through-indicator-42", "https://www.nasdaq.com/articles/whats-in-the-cards-for-merrimack-mack-in-q1-earnings-2017-04-27", "https://www.nasdaq.com/articles/are-options-traders-betting-on-a-big-move-in-merrimack-mack-stock-2017-03-31", "https://www.nasdaq.com/articles/merrimack-mack-starts-enrollment-in-solid-tumors-study-2017-03-24", "https://www.nasdaq.com/articles/health-care-sector-update-05262017-kitesensmack-2017-05-26", "https://www.nasdaq.com/articles/health-care-sector-update-03012017-mack-2017-03-01", "https://www.nasdaq.com/articles/merrimacks-mack-q4-loss-line-estimates-2017-03-01", "https://www.nasdaq.com/articles/earnings-reaction-history-merrimack-pharmaceuticals-inc-364-follow-through-indicator-79", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-inc-mack-stock-soars-on-ipsen-deal-2017-01-09", "https://www.nasdaq.com/articles/heres-why-merrimack-pharmaceuticals-inc-fell-473-2016-2017-01-09", "https://www.nasdaq.com/articles/why-merrimack-pharmaceuticals-stock-roaring-higher-today-2017-01-09", "https://www.nasdaq.com/articles/pre-market-most-active-jan-9-2017-aria-mack-smi-bac-tlt-mpel-fit-rio-arwr-nvs-vale-tvix", "https://www.nasdaq.com/articles/merrimack-mack-goes-uphill%3A-is-a-turnaround-likely-2017-01-17", "https://www.nasdaq.com/articles/is-the-options-market-predicting-a-spike-in-merrimack-mack-stock-2017-01-11", "https://www.nasdaq.com/articles/company-news-for-january-10-2017-2017-01-10", "https://www.nasdaq.com/articles/pre-market-most-active-jan-10-2017-wmb-vrx-ing-ugp-fcx-ttm-vod-tlt-tvix-mack-qqq-ilmn-2017", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-inc-mack-stock-soars-on-ipsen-deal-2017-01-09", "https://www.nasdaq.com/articles/heres-why-merrimack-pharmaceuticals-inc-fell-473-2016-2017-01-09", "https://www.nasdaq.com/articles/health-care-sector-update-12212016-calabmymrusincymack-2016-12-21", "https://www.nasdaq.com/articles/merrimack-mack-q3-loss-lower-than-expected-stock-up-2016-11-11", "https://www.nasdaq.com/articles/merrimack-mack-sells-onivyde-rights-to-ipsen-for-%241b-2017-01-09", "https://www.nasdaq.com/articles/heres-why-these-biopharma-stocks-soared-least-10-today-2016-11-09", "https://www.nasdaq.com/articles/health-care-sector-update-11092016-mackscmpcyh-2016-11-09", "https://www.nasdaq.com/articles/earnings-reaction-history-merrimack-pharmaceuticals-inc-400-follow-through-indicator-71", "https://www.nasdaq.com/articles/merrimack-mack%3A-what-awaits-the-stock-in-q3-earnings-2016-11-08", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack-worth-a-look%3A-stock-up-8.2-2016-10-24", "https://www.nasdaq.com/articles/shire-cancer-drug-onivyde-receives-eu-marketing-approval-2016-10-19", "https://www.nasdaq.com/articles/will-positive-phase-3-results-get-merrimack-back-track-2016-10-14", "https://www.nasdaq.com/articles/why-merrimack-pharmaceuticals-inc-shares-sank-18-lower-october-2016-11-09", "https://www.nasdaq.com/articles/merrimacks-onivyde-positive-in-pancreatic-cancer-study-2016-10-12", "https://www.nasdaq.com/articles/why-merrimack-pharmaceuticals-inc-rose-38-september-2016-10-10", "https://www.nasdaq.com/articles/company-news-for-october-04-2016-2016-10-04", "https://www.nasdaq.com/articles/health-care-sector-update-10032016-mylwfcrmrfvemack-2016-10-03", "https://www.nasdaq.com/articles/health-care-sector-update-10032016-cxrxfvemack-2016-10-03", "https://www.nasdaq.com/articles/why-merrimack-pharmaceuticals-inc-fell-203-august-2016-09-12", "https://www.nasdaq.com/articles/what-makes-merrimack-pharmaceuticals-mack-a-strong-sell-2016-08-29", "https://www.nasdaq.com/articles/how-risky-merrimack-pharmaceuticals-stock-2016-10-13", "https://www.nasdaq.com/articles/merrimacks-onivyde-positive-in-pancreatic-cancer-study-2016-10-12", "https://www.nasdaq.com/articles/merrimack-mack%3A-can-the-stock-surprise-in-q2-earnings-2016-08-01", "https://www.nasdaq.com/articles/ziopharm-ziop-stock-down-on-patient-death-in-phase-i-2016-07-18", "https://www.nasdaq.com/articles/celgenes-revlimid-gains-eu-nod-for-mantle-cell-lymphoma-2016-07-18", "https://www.nasdaq.com/articles/gileads-hcv-drug-epclusa-gets-regulatory-nod-in-canada-2016-07-15", "https://www.nasdaq.com/articles/ultragenyx-rare-reports-positive-phase-iii-rhgus-data-2016-07-15", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-stock-sank-stone-june-2016-07-13", "https://www.nasdaq.com/articles/merrimack-mack-q2-loss-wider-than-expected-sales-top-2016-08-05", "https://www.nasdaq.com/articles/comeback-juno-juno-stock-fda-lifts-clinical-hold-2016-07-13", "https://www.nasdaq.com/articles/bayer-expands-drug-discovery-collaboration-with-x-chem-2016-07-13", "https://www.nasdaq.com/articles/merrimack-stock-up-on-fast-track-status-for-seribantumab-2016-07-07", "https://www.nasdaq.com/articles/buy-5-attractive-biotechs-at-bargain-prices-2016-07-05", "https://www.nasdaq.com/articles/add-parts-xbi-could-be-worth-80-2016-06-28", "https://www.nasdaq.com/articles/heres-why-merrimack-pharmaceuticals-stock-has-been-getting-crushed-2016-2016-06-27", "https://www.nasdaq.com/articles/biodelivery-sciences-bdsi-catches-eye%3A-stock-rises-12-2016-07-13", "https://www.nasdaq.com/articles/cytrx-cytr-stock-falls-on-unfavorable-aldoxorubicin-data-2016-07-13", "https://www.nasdaq.com/articles/merrimack-baxalta-start-study-on-colorectal-cancer-drug-2016-05-20", "https://www.nasdaq.com/articles/why-merrimack-pharmaceuticals-stock-sliding-today-2016-05-03", "https://www.nasdaq.com/articles/merrimack-mack-posts-narrower-than-expected-loss-in-q1-2016-05-03", "https://www.nasdaq.com/articles/earnings-reaction-history-merrimack-pharmaceuticals-inc-444-follow-through-indicator-88", "https://www.nasdaq.com/articles/merrimack-mack-q1-earnings%3A-whats-ahead-for-the-stock-2016-04-27", "https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-juno-therapeutics-genocea-biosciences-merrimack", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-merrimack-pharmaceuticals-retrophin-idera", "https://www.nasdaq.com/articles/mack-makes-bullish-cross-above-critical-moving-average-2016-04-07", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-inc-rose-28-march-heres-why-2016-04-07", "https://www.nasdaq.com/articles/merrimack-director-buys-15000-shares-2016-03-04", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack-jumps%3A-stock-rises-12.6-2016-03-02", "https://www.nasdaq.com/articles/why-merrimack-pharmaceuticals-inc-shares-are-races-2016-03-01", "https://www.nasdaq.com/articles/merrimack-q4-loss-in-line-with-estimates-revenues-miss-2016-02-26", "https://www.nasdaq.com/articles/whats-in-store-for-merrimack-mack-this-earnings-season-2016-02-22", "https://www.nasdaq.com/articles/3-biotech-stocks-scary-high-debt-capital-ratios-2016-04-11", "https://www.nasdaq.com/articles/mack-makes-bullish-cross-above-critical-moving-average-2016-04-07", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-inc-rose-28-march-heres-why-2016-04-07", "https://www.nasdaq.com/articles/merrimack-alters-endpoint-in-cancer-drug-trial-raises-funds-2015-12-23", "https://www.nasdaq.com/articles/momentas-cancer-study-enrolment-put-on-temporary-hold-2015-11-16", "https://www.nasdaq.com/articles/why-merrimack-pharmaceuticals-inc-selling-today-2015-11-10", "https://www.nasdaq.com/articles/merrimack-mack-reports-narrower-than-expected-q3-loss-2015-11-10", "https://www.nasdaq.com/articles/earnings-reaction-history-merrimack-pharmaceuticals-inc-333-follow-through-indicator-71", "https://www.nasdaq.com/articles/math-shows-ihe-can-go-203-2016-02-16", "https://www.nasdaq.com/articles/after-hours-most-active-feb-9-2016-bac-ete-rf-etp-epd-rdn-mu-qqq-scty-mack-msft-2016-02-09", "https://www.nasdaq.com/articles/merrimack-reports-positive-onivyde-data-in-pancreatic-cancer-2016-01-20", "https://www.nasdaq.com/articles/merrimack-alters-endpoint-in-cancer-drug-trial-raises-funds-2015-12-23", "https://www.nasdaq.com/articles/momentas-cancer-study-enrolment-put-on-temporary-hold-2015-11-16", "https://www.nasdaq.com/articles/why-merrimack-pharmaceuticals-inc-selling-today-2015-11-10", "https://www.nasdaq.com/articles/merrimack-mack-reports-narrower-than-expected-q3-loss-2015-11-10", "https://www.nasdaq.com/articles/earnings-reaction-history-merrimack-pharmaceuticals-inc-333-follow-through-indicator-71", "https://www.nasdaq.com/articles/math-shows-ihe-can-go-203-2016-02-16", "https://www.nasdaq.com/articles/will-merrimack-mack-surprise-estimates-in-q3-earnings-2015-11-06", "https://www.nasdaq.com/articles/will-intercept-icpt-beat-estimates-in-q3-earnings-2015-11-06", "https://www.nasdaq.com/articles/catalyst-pharmaceutical-cprx%3A-a-peek-into-q3-earnings-2015-11-06", "https://www.nasdaq.com/articles/will-inovio-ino-disappoint-investors-this-earnings-season-2015-11-06", "https://www.nasdaq.com/articles/what-awaits-ligand-pharmaceuticals-lgnd-in-q3-earnings-2015-11-05", "https://www.nasdaq.com/articles/will-isis-pharmaceuticals-isis-surprise-in-q3-earnings-2015-11-05", "https://www.nasdaq.com/articles/is-intrexon-xon-likely-to-disappoint-this-earnings-season-2015-11-06", "https://www.nasdaq.com/articles/will-puma-biotechnology-pbyi-surprise-in-q3-earnings-2015-11-06", "https://www.nasdaq.com/articles/will-merrimack-mack-surprise-estimates-in-q3-earnings-2015-11-06", "https://www.nasdaq.com/articles/will-intercept-icpt-beat-estimates-in-q3-earnings-2015-11-06", "https://www.nasdaq.com/articles/catalyst-pharmaceutical-cprx%3A-a-peek-into-q3-earnings-2015-11-06", "https://www.nasdaq.com/articles/will-inovio-ino-disappoint-investors-this-earnings-season-2015-11-06", "https://www.nasdaq.com/articles/what-awaits-ligand-pharmaceuticals-lgnd-in-q3-earnings-2015-11-05", "https://www.nasdaq.com/articles/will-isis-pharmaceuticals-isis-surprise-in-q3-earnings-2015-11-05", "https://www.nasdaq.com/articles/is-intrexon-xon-likely-to-disappoint-this-earnings-season-2015-11-06", "https://www.nasdaq.com/articles/whats-in-store-for-repros-rprx-this-earnings-season-2015-11-05", "https://www.nasdaq.com/articles/celgene-celg-to-report-q3-earnings%3A-what-to-expect-2015-11-04", "https://www.nasdaq.com/articles/horizon-hznp%3A-whats-in-store-this-earnings-season-2015-11-04", "https://www.nasdaq.com/articles/will-agios-agio-disappoint-investors-this-earnings-season-2015-11-04", "https://www.nasdaq.com/articles/quanta-services-pwr-q3-earnings%3A-will-it-disappoint-2015-11-03", "https://www.nasdaq.com/articles/synta-snta-q3-earnings-preview%3A-whats-in-the-cards-2015-11-03", "https://www.nasdaq.com/articles/can-endo-internationals-endp-q3-earnings-surprise-2015-11-03", "https://www.nasdaq.com/articles/will-biodelivery-bdsi-disappoint-estimates-in-q3-earnings-2015-11-05", "https://www.nasdaq.com/articles/will-aerie-aeri-post-wider-expected-loss-q3-2015-11-02", "https://www.nasdaq.com/articles/will-aveo-aveo-pull-a-surprise-this-earnings-season-2015-11-02", "https://www.nasdaq.com/articles/whats-in-store-for-conatus-cnat-this-earnings-season-2015-11-02", "https://www.nasdaq.com/articles/what-to-expect-from-radius-rdus-this-earnings-season-2015-11-02", "https://www.nasdaq.com/articles/can-celldex-cldx-surprise-estimates-in-q3-earnings-2015-11-02", "https://www.nasdaq.com/articles/whats-in-store-for-endocyte-ecyt-this-earnings-season-2015-11-02", "https://www.nasdaq.com/articles/friday-814-insider-buying-report-shlm-mack-2015-08-14", "https://www.nasdaq.com/articles/will-arenas-arna-q3-loss-be-narrower-expected-2015-10-30", "https://www.nasdaq.com/articles/can-mylan-myl-surprise-investors-this-earnings-season-2015-10-28", "https://www.nasdaq.com/articles/earnings-reaction-history-merrimack-pharmaceuticals-inc-250-follow-through-indicator-72", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack%3A-q2-earnings-preview-analyst-blog-2015-08-07", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-stock-tanked-july-it-now-buy-2015-08-07", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-enters-oversold-territory-mack-2015-07-21", "https://www.nasdaq.com/articles/baxters-maa-for-mm-398-accepted-in-international-markets-analyst-blog-2015-06-29", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack-catches-eye%3A-stock-up-5.8-2015-08-12", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-q2-loss-wider-revenues-up-analyst-blog-2015-08-11", "https://www.nasdaq.com/articles/why-merrimack-pharmaceuticals-inc-soaring-today-2015-08-11", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-q1-loss-wider-than-expected-analyst-blog-2015-05-08", "https://www.nasdaq.com/articles/earnings-reaction-history-merrimack-pharmaceuticals-inc-286-follow-through-indicator-76", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack%3A-a-miss-this-earnings-analyst-blog-2015-05-05", "https://www.nasdaq.com/articles/first-week-december-18th-options-trading-merrimack-pharmaceuticals-mack-2015-04-27", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-q4-loss-narrower-than-expected-analyst-blog-2015-02-27", "https://www.nasdaq.com/articles/health-care-sector-update-06252015-oprn-espr-mack-2015-06-25", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mm-398-in-breast-cancer-study-analyst-blog-2015-06-15", "https://www.nasdaq.com/articles/merrimack-reveals-additional-data-from-oncology-candidate-analyst-blog-2015-01-22", "https://www.nasdaq.com/articles/after-hours-most-active-jan-20-2015-bac-pfe-emc-aapl-qqq-nflx-fcx-intc-jpm-ibm-gild-mack", "https://www.nasdaq.com/articles/friday-1226-insider-buying-report-mack-2014-12-26", "https://www.nasdaq.com/articles/insiders-bullish-certain-holdings-xbi-2014-12-24", "https://www.nasdaq.com/articles/health-care-sector-update-11212014-orex-mack-2014-11-21", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack-loss-narrows-in-q4-tale-of-the-tape-2015-02-26", "https://www.nasdaq.com/articles/will-inovio-ino-disappoint-expectations-for-q3-earnings-analyst-blog-2014-11-07", "https://www.nasdaq.com/articles/can-merrimack-mack-keep-the-earnings-streak-alive-in-q3-analyst-blog-2014-11-07", "https://www.nasdaq.com/articles/is-a-surprise-coming-for-merrimack-pharmaceuticals-mack-this-earnings-season-tale-of-the", "https://www.nasdaq.com/articles/whats-in-store-for-trovagene-trov-this-earnings-season-analyst-blog-2014-11-05", "https://www.nasdaq.com/articles/will-humana-hum-miss-on-earnings-estimates-this-season-analyst-blog-2014-11-04", "https://www.nasdaq.com/articles/prosensa-holding-n.v.-rna-jumps%3A-stock-moves-up-9.9-tale-of-the-tape-2014-11-03", "https://www.nasdaq.com/articles/alder-biopharmaceuticals-aldr-jumps%3A-stock-rises-6.5-tale-of-the-tape-2014-11-03", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mm-398-gets-fast-track-status-analyst-blog-2014-11-20", "https://www.nasdaq.com/articles/cara-therapeutics-cara-worth-watching%3A-stock-rises-6.4-tale-of-the-tape-2014-10-30", "https://www.nasdaq.com/articles/verastem-vstm-shows-strength%3A-stock-adds-7-in-session-tale-of-the-tape-2014-10-27", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack-shares-march-higher-can-it-continue-tale-of-the-tape-2014", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack-looks-strong%3A-stock-up-8.6-tale-of-the-tape-2014-10-24", "https://www.nasdaq.com/articles/3-biotech-stocks-near-52-week-highs-worth-selling-2014-10-22", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-regn-jumps%3A-stock-up-8.5-tale-of-the-tape-2014-10-20", "https://www.nasdaq.com/articles/novavax-nvax-moves-up%3A-stock-adds-10.1-in-session-tale-of-the-tape-2014-10-17", "https://www.nasdaq.com/articles/bristol-myers-squibb-bmy-jumps%3A-stock-moves-up-8.9-tale-of-the-tape-2014-10-31", "https://www.nasdaq.com/articles/peregrine-pharmaceuticals-pphm-jumps%3A-stock-rises-10.7-tale-of-the-tape-2014-10-16", "https://www.nasdaq.com/articles/weakness-seen-in-momenta-pharmaceuticals-mnta%3A-stock-tumbles-13.5-tale-of-the-tape-2014-10", "https://www.nasdaq.com/articles/why-merrimack-mack-could-be-positioned-for-a-surge-tale-of-the-tape-2014-10-10", "https://www.nasdaq.com/articles/get-ready-be-surprised-earnings-season-screen-week-2014-10-07", "https://www.nasdaq.com/articles/how-merrimack-pharmaceuticals-mack-stock-stands-out-in-a-strong-industry-tale-of-the-tape", "https://www.nasdaq.com/articles/will-merrimack-mack-continue-to-surge-higher-tale-of-the-tape-2014-09-26", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack-soars%3A-stock-adds-7.4-is-session-tale-of-the-tape-2014-09", "https://www.nasdaq.com/articles/lexicon-pharmaceuticals-lxrx-jumps%3A-stock-rises-15.7-tale-of-the-tape-2014-10-17", "https://www.nasdaq.com/articles/why-merrimack-pharmaceuticals-inc-stock-soaring-today-2014-09-24", "https://www.nasdaq.com/articles/us-stocks-seen-opening-higher-after-3-day-decline-home-sales-data-ecb-provides-boost", "https://www.nasdaq.com/articles/sector-update-health-care-2014-09-24-0", "https://www.nasdaq.com/articles/sector-update-health-care-shares-flat-pre-market-2014-09-24", "https://www.nasdaq.com/articles/pre-market-most-active-sep-24-2014-aapl-gsk-mack-avnr-san-baba-acor-siri-tvix-nok-bac-azn", "https://www.nasdaq.com/articles/us-futures-gain-ahead-new-home-sales-ecbs-draghi-voices-support-markets-2014-09-24", "https://www.nasdaq.com/articles/insider-bets-paying-mack-new-52-week-high-reached-2014-09-24", "https://www.nasdaq.com/articles/baxter-and-merrimack-collaborate-on-drug-development-analyst-blog-2014-09-25", "https://www.nasdaq.com/articles/can-merrimack-pharmaceuticals-mack-run-higher-on-strong-earnings-estimate-revisions-tale", "https://www.nasdaq.com/articles/will-merrimack-pharmaceuticals-mack-crush-estimates-at-its-next-earnings-report-tale-of", "https://www.nasdaq.com/articles/insiders-buy-holdings-xbi-etf-2014-07-08", "https://www.nasdaq.com/articles/tuesday-624-insider-buying-report-mack-hero-2014-06-24", "https://www.nasdaq.com/articles/merrimack-falls-steeply-as-sanofi-returns-oncology-drug-rights-analyst-blog-2014-06-23", "https://www.nasdaq.com/articles/xbi-mnkd-mack-rgen-etf-outflow-alert-2014-06-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-endocyte-tumbles-merrimack-soars-pipeline-news-analyst-blog-2014-05", "https://www.nasdaq.com/articles/after-hours-most-active-sep-15-2014-qqq-vmw-bac-mack-oxy-yoku-siri-aa-cat-msft-csco-eric", "https://www.nasdaq.com/articles/pre-market-most-active-may-1-2014-nmr-s-mack-fet-yelp-fb-burl-tmus-2014-05-01", "https://www.nasdaq.com/articles/small-gains-healthcare-sector-merrimack-pharmaceuticals-soars-after-cancer-drug-trial", "https://www.nasdaq.com/articles/insiders-seeing-green-mack-new-52-week-high-2014-05-01", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-mack-2014-04-14", "https://www.nasdaq.com/articles/should-you-worry-about-the-short-interest-in-merrimack-mack-tale-of-the-tape-2014-03-05", "https://www.nasdaq.com/articles/after-hours-most-active-jan-21-2014-pg-amd-bac-bsbr-acg-ibm-mack-qqq-spls-cree-arcp-nuan", "https://www.nasdaq.com/articles/can-merrimack-pharmaceuticals-inc.-mack-continue-to-rise-tale-of-the-tape-2014-01-09", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-05-01", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack-jumps%3A-stock-rises-6.6-tale-of-the-tape-2013-12-03", "https://www.nasdaq.com/articles/sector-update-biotech-stocks-looking-strong-nasdaq-struggles-2013-12-02", "https://www.nasdaq.com/articles/update-on-merrimacks-mm-121-analyst-blog-2013-11-29", "https://www.nasdaq.com/articles/little-movement-healthcare-sector-mack-pharmaceuticals-rising-after-positive-indications-2", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-11-26-0", "https://www.nasdaq.com/articles/after-hours-most-active-nov-11-2013-qqq-bx-kmt-kkr-vlo-gm-fig-vphm-fb-mack-holx-wen-2013", "https://www.nasdaq.com/articles/pre-market-most-active-oct-30-2013-teva-s-wu-gm-nok-hca-fb-aria-bidu-exel-mack-soda-2013", "https://www.nasdaq.com/articles/insider-trading-buy-merrimack-pharmaceuticals-2013-12-03", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack-jumps%3A-stock-rises-6.6-tale-of-the-tape-2013-12-03", "https://www.nasdaq.com/articles/sector-update-biotech-stocks-looking-strong-nasdaq-struggles-2013-12-02", "https://www.nasdaq.com/articles/merrimack-progresses-with-mm-111-analyst-blog-2013-07-26", "https://www.nasdaq.com/articles/pre-market-most-active-jul-12-2013-jpm-bac-vod-fly-wfc-mack-siri-nok-hmc-znga-sprd-qqq", "https://www.nasdaq.com/articles/sanofi-mack-candidate-progresses-analyst-blog-2013-03-20", "https://www.nasdaq.com/articles/after-hours-most-active-nov-16-2012-sfd-qqq-win-tsn-msft-tss-bac-myl-zgnx-wm-mack-mmc-2012", "https://www.nasdaq.com/articles/street-research-merrimack-pharmaceuticals-expected-may-8-2012-05-03", "https://www.nasdaq.com/articles/merrimack-study-data-published-analyst-blog-2013-08-23", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-sets-new-terms-now-seeking-100-million-2012-03-26", "https://www.nasdaq.com/articles/10-us-ipos-planned-week-mar-26-2012-03-26", "https://www.nasdaq.com/articles/merrimack-prices-ipo-7-raising-100-million-proceeds-2012-03-28"], "Content": []}